Formulation, Development, Characterization & In-vivo Anti-diabetic Evaluation of Hesperidin Phytosome

The aim of the present investigation is to develop formulation, characterization & In-vivo Anti-diabetic Evaluation of Hesperidin Phytosome. The formulation was prepared using Lecithin 45 mg and cholesterol 15 mg, precisely weighed, were dissolved in 10 ml of chloroform in a round-bottom flask (RBF) and subjected to a 10-minute bath sonication. Organic solvents are removed using a rotary evaporator set to 45–50 degrees Celsius. A thin layer of phospholipid mixture formed after the solvent was completely removed. Hesperidine rotary evaporator was used to hydrate this film for one hour at 37–40°C. Transmission electron microscopy was used to examine the morphology of Phytosomes. After being applied to 400 mesh carbon-coated copper grids, the phytosome dispersions were negatively stained using 1% w/v phosphotungstic acid. The Malvern mastersizer S laser diffraction size analyzer (Malvern Instruments Ltd., UK) was used to examine the phytosomes' size distribution. Using the methodology previously described in the literature, the in vivo anti-diabetic activity was assessed. Wistar rats weighing 150–200 g were purchased and kept in the Animal House Facility with 12-hour cycles of light and dark. The diagnostic kit (ERBA Diagnostic Mannheim, Germany) in Autoanalyser was used to estimate the biochemical parameters. The F1 and F2 batches were chosen as the optimal formulation and subsequently assessed further based on morphology (digital photos and TEM), particle size, and encapsulation efficiency. Vesicles with sizes ranging from 100 nm to 500 nm were seen under a scanning electron microscope. The F1 and F2 phytosomes had an average size of 109.71 and 133.24 nm, respectively. There was less peripheral widening between the islets and acinar cells (exocrine tissue) in some areas; both cells now appear close to one another, indicating a return to normal. In summary, a formulation based on Phytosomes may be a useful strategy to increase therapeutic efficacy, lower dosage, and enhance dosage regimen. For their anti-diabetic properties to be claimed, more research involving human subjects must be confirmed.